Recombinant Human EIF3I Protein, N-His

Recombinant Human EIF3I Protein: Structure, Activity, and Application

Introduction

Recombinant proteins are proteins that are produced through genetic engineering techniques, where the DNA sequence of the desired protein is inserted into a host organism, such as bacteria or yeast. This allows for large-scale production of proteins that are otherwise difficult to obtain in their natural form. One such protein is the Recombinant Human EIF3I Protein, which plays a crucial role in protein synthesis and has various applications in research and medicine.

Structure of Recombinant Human EIF3I Protein

The Recombinant Human EIF3I Protein is a subunit of the eukaryotic translation initiation factor 3 (eIF3) complex, which is involved in the initiation of protein synthesis. It is composed of 294 amino acids and has a molecular weight of approximately 33 kDa. The protein has a conserved N-terminal domain and a C-terminal domain that is rich in proline and acidic residues. The N-terminal domain is responsible for binding to the eIF3 complex, while the C-terminal domain interacts with other proteins involved in translation initiation.

Activity of Recombinant Human EIF3I Protein

The main function of the Recombinant Human EIF3I Protein is to assist in the assembly of the eIF3 complex and regulate the initiation of protein synthesis. It does this by recognizing the 5′ cap structure of mRNA and recruiting other initiation factors to form the initiation complex. The protein also plays a role in the regulation of translation by interacting with various signaling pathways and modulating the activity of translation factors.

Application of Recombinant Human EIF3I Protein

Recombinant Human EIF3I Protein has various applications in both research and medicine. In research, it is used as a tool to study the mechanisms of translation initiation and its regulation. The protein can be expressed in different host organisms, and its activity can be manipulated to investigate its role in various cellular processes.

In medicine, Recombinant Human EIF3I Protein has been studied as a potential target for cancer therapy. Dysregulation of translation initiation has been linked to various forms of cancer, and targeting the eIF3 complex, including the EIF3I subunit, has shown promising results in inhibiting cancer cell growth. Furthermore, mutations in the EIF3I gene have been associated with intellectual disabilities, and the study of Recombinant Human EIF3I Protein can aid in understanding the underlying mechanisms of these conditions.

Conclusion

In summary, Recombinant Human EIF3I Protein is a crucial component of the eIF3 complex, involved in the initiation of protein synthesis. Its structure and activity make it a valuable tool for research and potential target for cancer therapy. Further studies on this protein can provide insights into its role in various cellular processes and its potential as a therapeutic target for various diseases.